AbbVie Inc.
ABBV · As of 2026-11-11
$294.98
·
2.35%
Latest close & trailing twelve-month yield
Adjusted close price
Annualized Compounded Stock Growth
Annual dividends — last 10 years
Stock Volatility
Details
Company overview — ABBV
| Symbol | ABBV |
| AssetType | Common Stock |
| Name | AbbVie Inc |
| Description |
ShowAbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. |
| CIK | 1551152 |
| Exchange | NYSE |
| Currency | USD |
| Country | USA |
| Sector | HEALTHCARE |
| Industry | DRUG MANUFACTURERS - GENERAL |
| Address |
Show1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, UNITED STATES, 60064-6400 |
| OfficialSite | https://www.abbvie.com |
| FiscalYearEnd | December |
| LatestQuarter | 2026-09-30 |
| MarketCapitalization | $509.50 Billion |
| EBITDA | $31.85 Billion |
| PERatio | 49.53 |
| PEGRatio | 0.592 |
| BookValue | -2.593 |
| DividendPerShare | 6.92 |
| DividendYield | 0.0235 |
| EPS | 5.82 |
| RevenuePerShareTTM | 37.32 |
| ProfitMargin | 15.70% |
| OperatingMarginTTM | 39.60% |
| ReturnOnAssetsTTM | 10.70% |
| ReturnOnEquityTTM | 62.30% |
| RevenueTTM | $66.01 Billion |
| GrossProfitTTM | $48.67 Billion |
| DilutedEPSTTM | 5.82 |
| QuarterlyEarningsGrowthYOY | 22.82 |
| QuarterlyRevenueGrowthYOY | 0.103 |
| AnalystTargetPrice | 306.42 |
| AnalystRatingStrongBuy | 7 |
| AnalystRatingBuy | 16 |
| AnalystRatingHold | 5 |
| AnalystRatingSell | 0 |
| AnalystRatingStrongSell | 1 |
| TrailingPE | 49.53 |
| ForwardPE | 18.15 |
| PriceToSalesRatioTTM | 7.72 |
| PriceToBookRatio | 245.29 |
| EVToRevenue | 8.96 |
| EVToEBITDA | 25.2 |
| Beta | 0.192 |
| 52WeekHigh | 302.93 |
| 52WeekLow | 188.25 |
| 50DayMovingAverage | 270.78 |
| 200DayMovingAverage | 238.22 |
| SharesOutstanding | 1,767,616,000 |
| SharesFloat | 1,764,470,000 |
| PercentInsiders | 0.110 |
| PercentInstitutions | 77.184 |
| DividendDate | 2027-02-16 |
| ExDividendDate | 2027-01-15 |